1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975. [PubMed] [Google Scholar]
2. Braunwald E. Heart failure. JACC Heart Fail. 2013;1:1–20. [PubMed] [Google Scholar]
3. Savarese G, D'Amario D. Sex Differences in Heart Failure. Adv Exp Med Biol. 2018;1065:529–544. [PubMed] [Google Scholar]
4. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsush*ta K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135:e146–e603. [PMC free article] [PubMed] [Google Scholar]
5. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3:7–11. [PMC free article] [PubMed] [Google Scholar]
6. Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M, Hemingway H, Cleland JG, McMurray JJV, Rahimi K. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018;391:572–580. [PMC free article] [PubMed] [Google Scholar]
7. Lesyuk W, Kriza C, Kolominsky-Rabas P. Cost-of-illness studies in heart failure: a systematic review 2004-2016. BMC Cardiovasc Disord. 2018;18:74. [PMC free article] [PubMed] [Google Scholar]
8. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CSP, Sato N, Shah AN, Gheorghiade M. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63:1123–1133. [PubMed] [Google Scholar]
9. Taylor CJ, Ryan R, Nichols L, Gale N, Hobbs FR, Marshall T. Survival following a diagnosis of heart failure in primary care. Fam Pract. 2017;34:161–168. [PMC free article] [PubMed] [Google Scholar]
10. Dokainish H, Teo K, Zhu J, Roy A, AlHabib KF, ElSayed A, Palileo-Villaneuva L, Lopez-Jaramillo P, Karaye K, Yusoff K, Orlandini A, Sliwa K, Mondo C, Lanas F, Prabhakaran D, Badr A, Elmaghawry M, Damasceno A, Tibazarwa K, Belley-Cote E, Balasubramanian K, Islam S, Yacoub MH, Huffman MD, Harkness K, Grinvalds A, McKelvie R, Bangdiwala SI, Yusuf S INTER-CHF Investigators. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. Lancet Glob Health. 2017;5:e665–e672. [PubMed] [Google Scholar]
11. Mamas MA, Sperrin M, Watson MC, Coutts A, Wilde K, Burton C, Kadam UT, Kwok CS, Clark AB, Murchie P, Buchan I, Hannaford PC, Myint PK. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur J Heart Fail. 2017;19:1095–1104. [PubMed] [Google Scholar]
12. Taylor CJ, Ordóñez-Mena JM, Roalfe AK, Lay-Flurrie S, Jones NR, Marshall T, Hobbs FDR. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study. BMJ. 2019;364:l223. [PMC free article] [PubMed] [Google Scholar]
13. Mensah GA, Wei GS, Sorlie PD, Fine LJ, Rosenberg Y, Kaufmann PG, Mussolino ME, Hsu LL, Addou E, Engelgau MM, Gordon D. Decline in Cardiovascular Mortality: Possible Causes and Implications. Circ Res. 2017;120:366–380. [PMC free article] [PubMed] [Google Scholar]
14. Tsao CW, Lyass A, Enserro D, Larson MG, Ho JE, Kizer JR, Gottdiener JS, Psaty BM, Vasan RS. Temporal Trends in the Incidence of and Mortality Associated With Heart Failure With Preserved and Reduced Ejection Fraction. JACC Heart Fail. 2018;6:678–685. [PMC free article] [PubMed] [Google Scholar]
15. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14:591–602. [PubMed] [Google Scholar]
16. Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, Devore AD, Yancy CW, Fonarow GC. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. J Am Coll Cardiol. 2017;70:2476–2486. [PubMed] [Google Scholar]
17. Henning RJ. Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction. World J Cardiol. 2020;12:7–25. [PMC free article] [PubMed] [Google Scholar]
18. Goyal P, Loop M, Chen L, Brown TM, Durant RW, Safford MM, Levitan EB. Causes and Temporal Patterns of 30-Day Readmission Among Older Adults Hospitalized With Heart Failure With Preserved or Reduced Ejection Fraction. J Am Heart Assoc. 2018:7. [PMC free article] [PubMed] [Google Scholar]
19. Ibrahim NE, Januzzi JL., Jr Established and Emerging Roles of Biomarkers in Heart Failure. Circ Res. 2018;123:614–629. [PubMed] [Google Scholar]
20. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13:368–378. [PMC free article] [PubMed] [Google Scholar]
21. Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012;21:365–371. [PubMed] [Google Scholar]
22. Cuomo A, Rodolico A, Galdieri A, Russo M, Campi G, Franco R, Bruno D, Aran L, Carannante A, Attanasio U, Tocchetti CG, Varricchi G, Mercurio V. Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients. Card Fail Rev. 2019;5:112–118. [PMC free article] [PubMed] [Google Scholar]
23. De Keulenaer GW, Brutsaert DL. Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. Circulation. 2011;123:1996–2004; discussion 2005. [PubMed] [Google Scholar]
24. Aziz F, Tk LA, Enweluzo C, Dutta S, Zaeem M. Diastolic heart failure: a concise review. J Clin Med Res. 2013;5:327–334. [PMC free article] [PubMed] [Google Scholar]
25. Federmann M, Hess OM. Differentiation between systolic and diastolic dysfunction. Eur Heart J. 1994;15 Suppl D:2–6. [PubMed] [Google Scholar]
26. Bloom MW, Greenberg B, Jaarsma T, Januzzi JL, Lam CSP, Maggioni AP, Trochu JN, Butler J. Heart failure with reduced ejection fraction. Nat Rev Dis Primers. 2017;3:17058. [PubMed] [Google Scholar]
27. Ouzounian M, Lee DS, Liu PP. Diastolic heart failure: mechanisms and controversies. Nat Clin Pract Cardiovasc Med. 2008;5:375–386. [PubMed] [Google Scholar]
28. Yoon S, Eom GH. Heart failure with preserved ejection fraction: present status and future directions. Exp Mol Med. 2019;51:1–9. [PMC free article] [PubMed] [Google Scholar]
29. Buggey J, Alenezi F, Yoon HJ, Phelan M, DeVore AD, Khouri MG, Schulte PJ, Velazquez EJ. Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization. ESC Heart Fail. 2017;4:432–439. [PMC free article] [PubMed] [Google Scholar]
30. DeVore AD, McNulty S, Alenezi F, Ersboll M, Vader JM, Oh JK, Lin G, Redfield MM, Lewis G, Semigran MJ, Anstrom KJ, Hernandez AF, Velazquez EJ. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. Eur J Heart Fail. 2017;19:893–900. [PMC free article] [PubMed] [Google Scholar]
31. Nagueh SF, Chang SM, Nabi F, Shah DJ, Estep JD. Cardiac Imaging in Patients With Heart Failure and Preserved Ejection Fraction. Circ Cardiovasc Imaging. 2017:10. [PubMed] [Google Scholar]
32. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation. 2002;105:1503–1508. [PubMed] [Google Scholar]
33. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11:507–515. [PubMed] [Google Scholar]
34. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953–1959. [PubMed] [Google Scholar]
35. Zile MR, Baicu CF, Ikonomidis JS, Stroud RE, Nietert PJ, Bradshaw AD, Slater R, Palmer BM, Van Buren P, Meyer M, Redfield MM, Bull DA, Granzier HL, LeWinter MM. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015;131:1247–1259. [PMC free article] [PubMed] [Google Scholar]
36. Van Aelst LNL, Arrigo M, Placido R, Akiyama E, Girerd N, Zannad F, Manivet P, Rossignol P, Badoz M, Sadoune M, Launay JM, Gayat E, Lam CSP, Cohen-Solal A, Mebazaa A, Seronde MF. Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion. Eur J Heart Fail. 2018;20:738–747. [PubMed] [Google Scholar]
37. Reddy YNV, Andersen MJ, Obokata M, Koepp KE, Kane GC, Melenovsky V, Olson TP, Borlaug BA. Arterial Stiffening With Exercise in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2017;70:136–148. [PMC free article] [PubMed] [Google Scholar]
38. Dhakal BP, Malhotra R, Murphy RM, Pappagianopoulos PP, Baggish AL, Weiner RB, Houstis NE, Eisman AS, Hough SS, Lewis GD. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction. Circ Heart Fail. 2015;8:286–294. [PMC free article] [PubMed] [Google Scholar]
39. Malhotra R, Bakken K, D'Elia E, Lewis GD. Cardiopulmonary Exercise Testing in Heart Failure. JACC Heart Fail. 2016;4:607–616. [PubMed] [Google Scholar]
40. Reddy YNV, Olson TP, Obokata M, Melenovsky V, Borlaug BA. Hemodynamic Correlates and Diagnostic Role of Cardiopulmonary Exercise Testing in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2018;6:665–675. [PMC free article] [PubMed] [Google Scholar]
41. Banning AP, Lewis NP, Northridge DB, Elborn JS, Hendersen AH. Perfusion/ventilation mismatch during exercise in chronic heart failure: an investigation of circulatory determinants. Br Heart J. 1995;74:27–33. [PMC free article] [PubMed] [Google Scholar]
42. D'Amario D, Migliaro S, Borovac JA, Restivo A, Vergallo R, Galli M, Leone AM, Montone RA, Niccoli G, Aspromonte N, Crea F. Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. Front Physiol. 2019;10:1347. [PMC free article] [PubMed] [Google Scholar]
43. Gevaert AB, Boen JRA, Segers VF, Van Craenenbroeck EM. Heart Failure With Preserved Ejection Fraction: A Review of Cardiac and Noncardiac Pathophysiology. Front Physiol. 2019;10:638. [PMC free article] [PubMed] [Google Scholar]
44. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–271. [PubMed] [Google Scholar]
45. Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tschöpe C, Leite-Moreira AF, Musters R, Niessen HW, Linke WA, Paulus WJ, Hamdani N. Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2016;4:312–324. [PubMed] [Google Scholar]
46. van Heerebeek L, Hamdani N, Falcão-Pires I, Leite-Moreira AF, Begieneman MP, Bronzwaer JG, van der Velden J, Stienen GJ, Laarman GJ, Somsen A, Verheugt FW, Niessen HW, Paulus WJ. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012;126:830–839. [PubMed] [Google Scholar]
47. Kötter S, Gout L, Von Frieling-Salewsky M, Müller AE, Helling S, Marcus K, Dos Remedios C, Linke WA, Krüger M. Differential changes in titin domain phosphorylation increase myofilament stiffness in failing human hearts. Cardiovasc Res. 2013;99:648–656. [PubMed] [Google Scholar]
48. Hamdani N, Bishu KG, von Frieling-Salewsky M, Redfield MM, Linke WA. Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. Cardiovasc Res. 2013;97:464–471. [PubMed] [Google Scholar]
49. Graziani F, Varone F, Crea F, Richeldi L. Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis. Eur J Heart Fail. 2018;20:1385–1391. [PubMed] [Google Scholar]
50. Leucker TM, Jones SP. Endothelial dysfunction as a nexus for endothelial cell-cardiomyocyte miscommunication. Front Physiol. 2014;5:328. [PMC free article] [PubMed] [Google Scholar]
51. Gevaert AB, Lemmens K, Vrints CJ, Van Craenenbroeck EM. Targeting Endothelial Function to Treat Heart Failure with Preserved Ejection Fraction: The Promise of Exercise Training. Oxid Med Cell Longev. 2017;2017:4865756. [PMC free article] [PubMed] [Google Scholar]
52. Gimbrone MA, Jr, García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res. 2016;118:620–636. [PMC free article] [PubMed] [Google Scholar]
53. Kovacic JC, Dimmeler S, Harvey RP, Finkel T, Aikawa E, Krenning G, Baker AH. Endothelial to Mesenchymal Transition in Cardiovascular Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73:190–209. [PMC free article] [PubMed] [Google Scholar]
54. Wirrig EE, Yutzey KE. Conserved transcriptional regulatory mechanisms in aortic valve development and disease. Arterioscler Thromb Vasc Biol. 2014;34:737–741. [PMC free article] [PubMed] [Google Scholar]
55. Spillmann F, Miteva K, Pieske B, Tschöpe C, Van Linthout S. High-density lipoproteins reduce endothelial-to-mesenchymal transition. Arterioscler Thromb Vasc Biol. 2015;35:1774–1777. [PubMed] [Google Scholar]
56. Murdoch CE, Chaubey S, Zeng L, Yu B, Ivetic A, Walker SJ, Vanhoutte D, Heymans S, Grieve DJ, Cave AC, Brewer AC, Zhang M, Shah AM. Endothelial NADPH oxidase-2 promotes interstitial cardiac fibrosis and diastolic dysfunction through proinflammatory effects and endothelial-mesenchymal transition. J Am Coll Cardiol. 2014;63:2734–2741. [PubMed] [Google Scholar]
57. Cooley BC, Nevado J, Mellad J, Yang D, St Hilaire C, Negro A, Fang F, Chen G, San H, Walts AD, Schwartzbeck RL, Taylor B, Lanzer JD, Wragg A, Elagha A, Beltran LE, Berry C, Feil R, Virmani R, Ladich E, Kovacic JC, Boehm M. TGF-β signaling mediates endothelial-to-mesenchymal transition (EndMT) during vein graft remodeling. Sci Transl Med. 2014;6:227ra34. [PMC free article] [PubMed] [Google Scholar]
58. Xu X, Friehs I, Zhong Hu T, Melnychenko I, Tampe B, Alnour F, Iascone M, Kalluri R, Zeisberg M, Del Nido PJ, Zeisberg EM. Endocardial fibroelastosis is caused by aberrant endothelial to mesenchymal transition. Circ Res. 2015;116:857–866. [PMC free article] [PubMed] [Google Scholar]
59. Good RB, Gilbane AJ, Trinder SL, Denton CP, Coghlan G, Abraham DJ, Holmes AM. Endothelial to Mesenchymal Transition Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension. Am J Pathol. 2015;185:1850–1858. [PubMed] [Google Scholar]
60. Jiang Y, Zhou X, Hu R, Dai A. TGF-β1-induced SMAD2/3/4 activation promotes RELM-β transcription to modulate the endothelium-mesenchymal transition in human endothelial cells. Int J Biochem Cell Biol. 2018;105:52–60. [PubMed] [Google Scholar]
61. Piera-Velazquez S, Mendoza FA, Jimenez SA. Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases. J Clin Med. 2016:5. [PMC free article] [PubMed] [Google Scholar]
62. Yoshimura A, Wakabayashi Y, Mori T. Cellular and molecular basis for the regulation of inflammation by TGF-beta. J Biochem. 2010;147:781–792. [PMC free article] [PubMed] [Google Scholar]
63. Cho JG, Lee A, Chang W, Lee MS, Kim J. Endothelial to Mesenchymal Transition Represents a Key Link in the Interaction between Inflammation and Endothelial Dysfunction. Front Immunol. 2018;9:294. [PMC free article] [PubMed] [Google Scholar]
64. Hulshoff MS, Xu X, Krenning G, Zeisberg EM. Epigenetic Regulation of Endothelial-to-Mesenchymal Transition in Chronic Heart Disease. Arterioscler Thromb Vasc Biol. 2018;38:1986–1996. [PubMed] [Google Scholar]
65. Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017;14:30–38. [PMC free article] [PubMed] [Google Scholar]
66. Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond) 2016;130:57–77. [PMC free article] [PubMed] [Google Scholar]
67. Jhund PS, McMurray JJ. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart. 2016;102:1342–1347. [PMC free article] [PubMed] [Google Scholar]
68. Orsborne C, Chaggar PS, Shaw SM, Williams SG. The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future. Postgrad Med J. 2017;93:29–37. [PubMed] [Google Scholar]
69. Goldsmith SR. The role of vasopressin in congestive heart failure. Cleve Clin J Med. 2006;73 Suppl 3:S19–S23. [PubMed] [Google Scholar]
70. Lee CS, Tkacs NC. Current concepts of neurohormonal activation in heart failure: mediators and mechanisms. AACN Adv Crit Care. 2008;19:364–85; quiz 386-7. [PubMed] [Google Scholar]
71. Zhang DY, Anderson AS. The sympathetic nervous system and heart failure. Cardiol Clin. 2014;32:33–45, vii. [PMC free article] [PubMed] [Google Scholar]
72. Floras JS, Ponikowski P. The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction. Eur Heart J. 2015;36:1974–182b. [PMC free article] [PubMed] [Google Scholar]
73. Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF, de Boer RA, Drexel H, Ben Gal T, Hill L, Jaarsma T, Jankowska EA, Anker MS, Lainscak M, Lewis BS, McDonagh T, Metra M, Milicic D, Mullens W, Piepoli MF, Rosano G, Ruschitzka F, Volterrani M, Voors AA, Filippatos G, Coats AJS. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:1169–1186. [PubMed] [Google Scholar]
74. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147–e239. [PubMed] [Google Scholar]
75. van Bilsen M, Patel HC, Bauersachs J, Böhm M, Borggrefe M, Brutsaert D, Coats AJS, de Boer RA, de Keulenaer GW, Filippatos GS, Floras J, Grassi G, Jankowska EA, Kornet L, Lunde IG, Maack C, Mahfoud F, Pollesello P, Ponikowski P, Ruschitzka F, Sabbah HN, Schultz HD, Seferovic P, Slart RHJA, Taggart P, Tocchetti CG, Van Laake LW, Zannad F, Heymans S, Lyon AR. The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2017;19:1361–1378. [PubMed] [Google Scholar]
76. Doehner W, Ural D, Haeusler KG, Čelutkienė J, Bestetti R, Cavusoglu Y, Peña-Duque MA, Glavas D, Iacoviello M, Laufs U, Alvear RM, Mbakwem A, Piepoli MF, Rosen SD, Tsivgoulis G, Vitale C, Yilmaz MB, Anker SD, Filippatos G, Seferovic P, Coats AJS, Ruschitzka F. Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association. Eur J Heart Fail. 2018;20:199–215. [PubMed] [Google Scholar]
77. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248–254. [PubMed] [Google Scholar]
78. de Lucia C, Piedepalumbo M, Paolisso G, Koch WJ. Sympathetic nervous system in age-related cardiovascular dysfunction: Pathophysiology and therapeutic perspective. Int J Biochem Cell Biol. 2019;108:29–33. [PMC free article] [PubMed] [Google Scholar]
79. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009;54:1747–1762. [PubMed] [Google Scholar]
80. Angelakos ET, King MP, Millard RW. Regional distribution of catecholamines in the hearts of various species. Ann N Y Acad Sci. 1969;156:219–240. [PubMed] [Google Scholar]
81. Pierpont GL, DeMaster EG, Reynolds S, Pederson J, Cohn JN. Ventricular myocardial catecholamines in primates. J Lab Clin Med. 1985;106:205–210. [PubMed] [Google Scholar]
82. Janes RD, Brandys JC, Hopkins DA, Johnstone DE, Murphy DA, Armour JA. Anatomy of human extrinsic cardiac nerves and ganglia. Am J Cardiol. 1986;57:299–309. [PubMed] [Google Scholar]
83. Heesch CM. Reflexes that control cardiovascular function. Am J Physiol. 1999;277:S234–S243. [PubMed] [Google Scholar]
84. Burchell AE, Sobotka PA, Hart EC, Nightingale AK, Dunlap ME. Chemohypersensitivity and autonomic modulation of venous capacitance in the pathophysiology of acute decompensated heart failure. Curr Heart Fail Rep. 2013;10:139–146. [PubMed] [Google Scholar]
85. Fallick C, Sobotka PA, Dunlap ME. Sympathetically mediated changes in capacitance: redistribution of the venous reservoir as a cause of decompensation. Circ Heart Fail. 2011;4:669–675. [PubMed] [Google Scholar]
86. Malliani A, Montano N. Emerging excitatory role of cardiovascular sympathetic afferents in pathophysiological conditions. Hypertension. 2002;39:63–68. [PubMed] [Google Scholar]
87. Leineweber K, Wangemann T, Giessler C, Bruck H, Dhein S, Kostelka M, Mohr FW, Silber RE, Brodde OE. Age-dependent changes of cardiac neuronal noradrenaline reuptake transporter (uptake1) in the human heart. J Am Coll Cardiol. 2002;40:1459. [PubMed] [Google Scholar]
88. Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci. 2003;4:13–25. [PubMed] [Google Scholar]
89. Rengo G, Pagano G, Vitale DF, Formisano R, Komici K, Petraglia L, Parisi V, Femminella GD, de Lucia C, Paolillo S, Cannavo A, Attena E, Pellegrino T, Dellegrottaglie S, Memmi A, Trimarco B, Cuocolo A, Filardi PP, Leosco D, Ferrara N. Impact of aging on cardiac sympathetic innervation measured by 123I-mIBG imaging in patients with systolic heart failure. Eur J Nucl Med Mol Imaging. 2016;43:2392–2400. [PubMed] [Google Scholar]
90. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, Agostini D, Weiland F, Chandna H, Narula J ADMIRE-HF Investigators. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55:2212–2221. [PubMed] [Google Scholar]
91. de Diego AM, Gandía L, García AG. A physiological view of the central and peripheral mechanisms that regulate the release of catecholamines at the adrenal medulla. Acta Physiol (Oxf) 2008;192:287–301. [PubMed] [Google Scholar]
92. Philipp M, Hein L. Adrenergic receptor knockout mice: distinct functions of 9 receptor subtypes. Pharmacol Ther. 2004;101:65–74. [PubMed] [Google Scholar]
93. Rozec B, Gauthier C. beta3-adrenoceptors in the cardiovascular system: putative roles in human pathologies. Pharmacol Ther. 2006;111:652–673. [PubMed] [Google Scholar]
94. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature. 2002;415:206–212. [PubMed] [Google Scholar]
95. Gauthier C, Leblais V, Kobzik L, Trochu JN, Khandoudi N, Bril A, Balligand JL, Le Marec H. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest. 1998;102:1377–1384. [PMC free article] [PubMed] [Google Scholar]
96. Myagmar BE, Flynn JM, Cowley PM, Swigart PM, Montgomery MD, Thai K, Nair D, Gupta R, Deng DX, Hosoda C, Melov S, Baker AJ, Simpson PC. Adrenergic Receptors in Individual Ventricular Myocytes: The Beta-1 and Alpha-1B Are in All Cells, the Alpha-1A Is in a Subpopulation, and the Beta-2 and Beta-3 Are Mostly Absent. Circ Res. 2017;120:1103–1115. [PMC free article] [PubMed] [Google Scholar]
97. Reid JL. Alpha-adrenergic receptors and blood pressure control. Am J Cardiol. 1986;57:6E–12E. [PubMed] [Google Scholar]
98. Becker BK, Speed JS, Powell M, Pollock DM. Activation of neuronal endothelin B receptors mediates pressor response through alpha-1 adrenergic receptors. Physiol Rep. 2017;5 [PMC free article] [PubMed] [Google Scholar]
99. Woo AY, Xiao RP. β-Adrenergic receptor subtype signaling in heart: from bench to bedside. Acta Pharmacol Sin. 2012;33:335–341. [PMC free article] [PubMed] [Google Scholar]
100. Ali DC, Naveed M, Gordon A, Majeed F, Saeed M, Ogbuke MI, Atif M, Zubair HM, Changxing L. β-Adrenergic receptor, an essential target in cardiovascular diseases. Heart Fail Rev. 2020;25:343–354. [PubMed] [Google Scholar]
101. Madamanchi A. Beta-adrenergic receptor signaling in cardiac function and heart failure. Mcgill J Med. 2007;10:99–104. [PMC free article] [PubMed] [Google Scholar]
102. Baruscotti M, Barbuti A, Bucchi A. The cardiac pacemaker current. J Mol Cell Cardiol. 2010;48:55–64. [PubMed] [Google Scholar]
103. Santulli G, Iaccarino G. Pinpointing beta adrenergic receptor in ageing pathophysiology: victim or executioner? Evidence from crime scenes. Immun Ageing. 2013;10:10. [PMC free article] [PubMed] [Google Scholar]
104. Collins S, Cao W, Robidoux J. Learning new tricks from old dogs: beta-adrenergic receptors teach new lessons on firing up adipose tissue metabolism. Mol Endocrinol. 2004;18:2123–2131. [PubMed] [Google Scholar]
105. Napp A, Brixius K, Pott C, Ziskoven C, Boelck B, Mehlhorn U, Schwinger RH, Bloch W. Effects of the beta3-adrenergic agonist BRL 37344 on endothelial nitric oxide synthase phosphorylation and force of contraction in human failing myocardium. J Card Fail. 2009;15:57–67. [PubMed] [Google Scholar]
106. Dessy C, Moniotte S, Ghisdal P, Havaux X, Noirhomme P, Balligand JL. Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation. 2004;110:948–954. [PubMed] [Google Scholar]
107. Dessy C, Balligand JL. Beta3-adrenergic receptors in cardiac and vascular tissues emerging concepts and therapeutic perspectives. Adv Pharmacol. 2010;59:135–163. [PubMed] [Google Scholar]
108. Imbrogno S, Angelone T, Adamo C, Pulerà E, Tota B, Cerra MC. Beta3-adrenoceptor in the eel (Anguilla anguilla) heart: negative inotropy and NO-cGMP-dependent mechanism. J Exp Biol. 2006;209:4966–4973. [PubMed] [Google Scholar]
109. Moniotte S, Belge C, Sekkali B, Massion PB, Rozec B, Dessy C, Balligand JL. Sepsis is associated with an upregulation of functional beta3 adrenoceptors in the myocardium. Eur J Heart Fail. 2007;9:1163–1171. [PubMed] [Google Scholar]
110. Gauthier C, Rozec B, Manoury B, Balligand JL. Beta-3 adrenoceptors as new therapeutic targets for cardiovascular pathologies. Curr Heart Fail Rep. 2011;8:184–192. [PubMed] [Google Scholar]
111. Rozec B, Erfanian M, Laurent K, Trochu JN, Gauthier C. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J Am Coll Cardiol. 2009;53:1532–1538. [PubMed] [Google Scholar]
112. Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva II, Frérart F, Belge C, Jnaoui K, Noirhomme P, Feron O, Balligand JL. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation. 2005;112:1198–1205. [PubMed] [Google Scholar]
113. de Lucia C, Eguchi A, Koch WJ. New Insights in Cardiac β-Adrenergic Signaling During Heart Failure and Aging. Front Pharmacol. 2018;9:904. [PMC free article] [PubMed] [Google Scholar]
114. Gurevich VV, Gurevich EV. GPCR Signaling Regulation: The Role of GRKs and Arrestins. Front Pharmacol. 2019;10:125. [PMC free article] [PubMed] [Google Scholar]
115. Shukla AK, Xiao K, Lefkowitz RJ. Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem Sci. 2011;36:457–469. [PMC free article] [PubMed] [Google Scholar]
116. Sato PY, Chuprun JK, Schwartz M, Koch WJ. The evolving impact of g protein-coupled receptor kinases in cardiac health and disease. Physiol Rev. 2015;95:377–404. [PMC free article] [PubMed] [Google Scholar]
117. Swedberg K, Viquerat C, Rouleau JL, Roizen M, Atherton B, Parmley WW, Chatterjee K. Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. Am J Cardiol. 1984;54:783–786. [PubMed] [Google Scholar]
118. Viquerat CE, Daly P, Swedberg K, Evers C, Curran D, Parmley WW, Chatterjee K. Endogenous catecholamine levels in chronic heart failure. Relation to the severity of hemodynamic abnormalities. Am J Med. 1985;78:455–460. [PubMed] [Google Scholar]
119. Kaye DM, Lambert GW, Lefkovits J, Morris M, Jennings G, Esler MD. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol. 1994;23:570–578. [PubMed] [Google Scholar]
120. Aggarwal A, Esler MD, Lambert GW, Hastings J, Johnston L, Kaye DM. Norepinephrine turnover is increased in suprabulbar subcortical brain regions and is related to whole-body sympathetic activity in human heart failure. Circulation. 2002;105:1031–1033. [PubMed] [Google Scholar]
121. Zucker IH, Schultz HD, Patel KP, Wang W, Gao L. Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure. Am J Physiol Heart Circ Physiol. 2009;297:H1557–H1566. [PMC free article] [PubMed] [Google Scholar]
122. Gao L, Wang WZ, Wang W, Zucker IH. Imbalance of angiotensin type 1 receptor and angiotensin II type 2 receptor in the rostral ventrolateral medulla: potential mechanism for sympathetic overactivity in heart failure. Hypertension. 2008;52:708–714. [PMC free article] [PubMed] [Google Scholar]
123. Mäurer W, Tschada R, Manthey J, Ablasser A, Kübler W. Catecholamines in Patients with Heart Failure. In: Delius W, Gerlach E, Grobecker H, Kübler W, editors. Catecholamines and the Heart. Berlin, Heidelberg: Springer; 1981. pp. 236–246. [Google Scholar]
124. Chidsey CA, Braunwald E, Morrow AG. Catecholamine Excretion and Cardiac Stores of Norepinephrine in Congestive Heart Failure. Am J Med. 1965;39:442–451. [PubMed] [Google Scholar]
125. Ramchandra R, Hood SG, Denton DA, Woods RL, McKinley MJ, McAllen RM, May CN. Basis for the preferential activation of cardiac sympathetic nerve activity in heart failure. Proc Natl Acad Sci USA. 2009;106:924–928. [PMC free article] [PubMed] [Google Scholar]
126. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995;26:1257–1263. [PubMed] [Google Scholar]
127. Ramchandra R, Barrett CJ. Regulation of the renal sympathetic nerves in heart failure. Front Physiol. 2015;6:238. [PMC free article] [PubMed] [Google Scholar]
128. Ramchandra R, Hood SG, Xing D, Lambert GW, May CN. Mechanisms underlying the increased cardiac norepinephrine spillover in heart failure. Am J Physiol Heart Circ Physiol. 2018;315:H340–H347. [PubMed] [Google Scholar]
129. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819–823. [PubMed] [Google Scholar]
130. Chidsey CA, Harrison DC, Braunwald E. Augmentation of the plasma nor-epinephrine response to exercise in patients with congestive heart failure. N Engl J Med. 1962;267:650–654. [PubMed] [Google Scholar]
131. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73:615–621. [PubMed] [Google Scholar]
132. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205–211. [PubMed] [Google Scholar]
133. Freedman NJ, Lefkowitz RJ. Anti-beta(1)-adrenergic receptor antibodies and heart failure: causation, not just correlation. J Clin Invest. 2004;113:1379–1382. [PMC free article] [PubMed] [Google Scholar]
134. Mangmool S, Parichatikanond W, Kurose H. Therapeutic Targets for Treatment of Heart Failure: Focus on GRKs and β-Arrestins Affecting βAR Signaling. Front Pharmacol. 2018;9:1336. [PMC free article] [PubMed] [Google Scholar]
135. Shah AS, White DC, Emani S, Kypson AP, Lilly RE, Wilson K, Glower DD, Lefkowitz RJ, Koch WJ. In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation. 2001;103:1311–1316. [PubMed] [Google Scholar]
136. Liu WN, Fu KL, Gao HY, Shang YY, Wang ZH, Jiang GH, Zhang Y, Zhang W, Zhong M. β1 adrenergic receptor polymorphisms and heart failure: a meta-analysis on susceptibility, response to β-blocker therapy and prognosis. PLoS One. 2012;7:e37659. [PMC free article] [PubMed] [Google Scholar]
137. Biolo A, Clausell N, Santos KG, Salvaro R, Ashton-Prolla P, Borges A, Rohde LE. Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy. Am J Cardiol. 2008;102:726–732. [PubMed] [Google Scholar]
138. Metaxa S, Missouris C, Mavrogianni D, Miliou A, Oikonomou E, Toli E, Kormali L, Vlismas A, Drakakis P, Tousoulis D. Polymorphism Gln27Glu of β2 Adrenergic Receptors in Patients with Ischaemic Cardiomyopathy. Curr Vasc Pharmacol. 2018;16:618–623. [PubMed] [Google Scholar]
139. Pezzali N, Curnis A, Specchia C, Carubelli V, Covolo L, Donato F, Auricchio A, Regoli F, Metra M. Adrenergic receptor gene polymorphism and left ventricular reverse remodelling after cardiac resynchronization therapy: preliminary results. Europace. 2013;15:1475–1481. [PubMed] [Google Scholar]
140. Katsuumi G, Shimizu I, Yoshida Y, Hayashi Y, Ikegami R, Suda M, Wakasugi T, Nakao M, Minamino T. Catecholamine-Induced Senescence of Endothelial Cells and Bone Marrow Cells Promotes Cardiac Dysfunction in Mice. Int Heart J. 2018;59:837–844. [PubMed] [Google Scholar]
141. Bonnefont-Rousselot D, Mahmoudi A, Mougenot N, Varoquaux O, Le Nahour G, Fouret P, Lechat P. Catecholamine effects on cardiac remodelling, oxidative stress and fibrosis in experimental heart failure. Redox Rep. 2002;7:145–151. [PubMed] [Google Scholar]
142. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA. 1999;96:7059–7064. [PMC free article] [PubMed] [Google Scholar]
143. Richard C. Stress-related cardiomyopathies. Ann Intensive Care. 2011;1:39. [PMC free article] [PubMed] [Google Scholar]
144. Chesley A, Lundberg MS, Asai T, Xiao RP, Ohtani S, Lakatta EG, Crow MT. The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3'-kinase. Circ Res. 2000;87:1172–1179. [PubMed] [Google Scholar]
145. Liggett SB, Tepe NM, Asai T, Lorenz JN, Canning AM, Jantz TD, Mitarai S, Yatani A, Dorn GW 2nd. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation. 2000;101:1707–1714. [PubMed] [Google Scholar]
146. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein. Circulation. 1999;100:2210–2212. [PubMed] [Google Scholar]
147. Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation. 1997;95:169–175. [PubMed] [Google Scholar]
148. Meredith IT, Broughton A, Jennings GL, Esler MD. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med. 1991;325:618–624. [PubMed] [Google Scholar]
149. Ishise H, Asanoi H, Ishizaka S, Joho S, Kameyama T, Umeno K, Inoue H. Time course of sympathovagal imbalance and left ventricular dysfunction in conscious dogs with heart failure. J Appl Physiol (1985) 1998;84:1234–1241. [PubMed] [Google Scholar]
150. Ferguson DW, Berg WJ, Roach PJ, Oren RM, Mark AL. Effects of heart failure on baroreflex control of sympathetic neural activity. Am J Cardiol. 1992;69:523–531. [PubMed] [Google Scholar]
151. Grassi G, Seravalle G, Bertinieri G, Turri C, Stella ML, Scopelliti F, Mancia G. Sympathetic and reflex abnormalities in heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. Clin Sci (Lond) 2001;101:141–146. [PubMed] [Google Scholar]
152. Ferguson DW, Abboud FM, Mark AL. Selective impairment of baroreflex-mediated vasoconstrictor responses in patients with ventricular dysfunction. Circulation. 1984;69:451–460. [PubMed] [Google Scholar]
153. Floras JS. Arterial baroreceptor and cardiopulmonary reflex control of sympathetic outflow in human heart failure. Ann N Y Acad Sci. 2001;940:500–513. [PubMed] [Google Scholar]
154. Grassi G, Seravalle G, Cattaneo BM, Lanfranchi A, Vailati S, Giannattasio C, Del Bo A, Sala C, Bolla GB, Pozzi M. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation. 1995;92:3206–3211. [PubMed] [Google Scholar]
155. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Bolla G, Mancia G. Effects of hypertension and obesity on the sympathetic activation of heart failure patients. Hypertension. 2003;42:873–877. [PubMed] [Google Scholar]
156. Gronda E, Seravalle G, Brambilla G, Costantino G, Casini A, Alsheraei A, Lovett EG, Mancia G, Grassi G. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. Eur J Heart Fail. 2014;16:977–983. [PMC free article] [PubMed] [Google Scholar]
157. Gronda E, Francis D, Zannad F, Hamm C, Brugada J, Vanoli E. Baroreflex activation therapy: a new approach to the management of advanced heart failure with reduced ejection fraction. J Cardiovasc Med (Hagerstown) 2017;18:641–649. [PMC free article] [PubMed] [Google Scholar]
158. Shen MJ, Zipes DP. Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res. 2014;114:1004–1021. [PubMed] [Google Scholar]
159. Franciosi S, Perry FKG, Roston TM, Armstrong KR, Claydon VE, Sanatani S. The role of the autonomic nervous system in arrhythmias and sudden cardiac death. Auton Neurosci. 2017;205:1–11. [PubMed] [Google Scholar]
160. Porter B, Bishop MJ, Claridge S, Behar J, Sieniewicz BJ, Webb J, Gould J, O'Neill M, Rinaldi CA, Razavi R, Gill JS, Taggart P. Autonomic Modulation in Patients with Heart Failure Increases Beat-to-Beat Variability of Ventricular Action Potential Duration. Front Physiol. 2017;8:328. [PMC free article] [PubMed] [Google Scholar]
161. Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye DM. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J. 2001;22:1136–1143. [PubMed] [Google Scholar]
162. f*ckuda K, Kanazawa H, Aizawa Y, Ardell JL, Shivkumar K. Cardiac innervation and sudden cardiac death. Circ Res. 2015;116:2005–2019. [PMC free article] [PubMed] [Google Scholar]
163. Fudim M, Boortz-Marx R, Ganesh A, Waldron NH, Qadri YJ, Patel CB, Milano CA, Sun AY, Mathew JP, Piccini JP. Stellate ganglion blockade for the treatment of refractory ventricular arrhythmias: A systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2017;28:1460–1467. [PubMed] [Google Scholar]
164. Meng L, Tseng CH, Shivkumar K, Ajijola O. Efficacy of Stellate Ganglion Blockade in Managing Electrical Storm: A Systematic Review. JACC Clin Electrophysiol. 2017;3:942–949. [PMC free article] [PubMed] [Google Scholar]
165. Fudim M, Qadri YJ, Waldron NH, Boortz-Marx RL, Ganesh A, Patel CB, Podgoreanu MV, Sun AY, Milano CA, Tong BC, Harpole DH, Jr, Mathew JP, Piccini JP. Stellate Ganglion Blockade for the Treatment of Refractory Ventricular Arrhythmias. JACC Clin Electrophysiol. 2020;6:562–571. [PubMed] [Google Scholar]
166. Zhou S, Jung BC, Tan AY, Trang VQ, Gholmieh G, Han SW, Lin SF, Fishbein MC, Chen PS, Chen LS. Spontaneous stellate ganglion nerve activity and ventricular arrhythmia in a canine model of sudden death. Heart Rhythm. 2008;5:131–139. [PubMed] [Google Scholar]
167. Wu P, Vaseghi M. The autonomic nervous system and ventricular arrhythmias in myocardial infarction and heart failure. Pacing Clin Electrophysiol. 2020;43:172–180. [PMC free article] [PubMed] [Google Scholar]
168. Waldron NH, Fudim M, Mathew JP, Piccini JP. Neuromodulation for the Treatment of Heart Rhythm Disorders. JACC Basic Transl Sci. 2019;4:546–562. [PMC free article] [PubMed] [Google Scholar]
169. Notarius CF, Ando S, Rongen GA, Floras JS. Resting muscle sympathetic nerve activity and peak oxygen uptake in heart failure and normal subjects. Eur Heart J. 1999;20:880–887. [PubMed] [Google Scholar]
170. Notarius CF, Azevedo ER, Parker JD, Floras JS. Peak oxygen uptake is not determined by cardiac noradrenaline spillover in heart failure. Eur Heart J. 2002;23:800–805. [PubMed] [Google Scholar]
171. Notarius CF, Spaak J, Morris BL, Floras JS. Comparison of muscle sympathetic activity in ischemic and nonischemic heart failure. J Card Fail. 2007;13:470–475. [PubMed] [Google Scholar]
172. Barrett-O'Keefe Z, Lee JF, Ives SJ, Trinity JD, Witman MAH, Rossman MJ, Groot HJ, Sorensen JR, Morgan DE, Nelson AD, Stehlik J, Richardson RS, Wray DW. α-Adrenergic receptor regulation of skeletal muscle blood flow during exercise in heart failure patients with reduced ejection fraction. Am J Physiol Regul Integr Comp Physiol. 2019;316:R512–R524. [PMC free article] [PubMed] [Google Scholar]
173. Colucci WS, Ribeiro JP, Rocco MB, Quigg RJ, Creager MA, Marsh JD, Gauthier DF, Hartley LH. Impaired chronotropic response to exercise in patients with congestive heart failure. Role of postsynaptic beta-adrenergic desensitization. Circulation. 1989;80:314–323. [PubMed] [Google Scholar]
174. Boutagy NE, Sinusas AJ. Imaging of the Cardiac Sympathetic Nervous System Has Potential Value in the Evaluation of Patients with Heart Failure with Preserved Ejection Fraction. J Nucl Med. 2017;58:781–783. [PMC free article] [PubMed] [Google Scholar]
175. Matsunari I, Aoki H, Nomura Y, Takeda N, Chen WP, Taki J, Nakajima K, Nekolla SG, Kinuya S, Kajinami K. Iodine-123 metaiodobenzylguanidine imaging and carbon-11 hydroxyephedrine positron emission tomography compared in patients with left ventricular dysfunction. Circ Cardiovasc Imaging. 2010;3:595–603. [PubMed] [Google Scholar]
176. Aikawa T, Naya M, Obara M, Manabe O, Tomiyama Y, Magota K, Yamada S, Katoh C, Tamaki N, Tsutsui H. Impaired Myocardial Sympathetic Innervation Is Associated with Diastolic Dysfunction in Heart Failure with Preserved Ejection Fraction: 11C-Hydroxyephedrine PET Study. J Nucl Med. 2017;58:784–790. [PubMed] [Google Scholar]
177. Aikawa T, Naya M, Obara M, Oyama-Manabe N, Manabe O, Magota K, Ito YM, Katoh C, Tamaki N. Regional interaction between myocardial sympathetic denervation, contractile dysfunction, and fibrosis in heart failure with preserved ejection fraction: 11C-hydroxyephedrine PET study. Eur J Nucl Med Mol Imaging. 2017;44:1897–1905. [PubMed] [Google Scholar]
178. Shah AM, Bourgoun M, Narula J, Jacobson AF, Solomon SD. Influence of ejection fraction on the prognostic value of sympathetic innervation imaging with iodine-123 MIBG in heart failure. JACC Cardiovasc Imaging. 2012;5:1139–1146. [PubMed] [Google Scholar]
179. Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S, Matsui T, Matsuo S, Travin MI, Jacobson AF. A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging. 2013;6:772–784. [PubMed] [Google Scholar]
180. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29:1147–1159. [PubMed] [Google Scholar]
181. Narula J, Gerson M, Thomas GS, Cerqueira MD, Jacobson AF. ¹²³I-MIBG Imaging for Prediction of Mortality and Potentially Fatal Events in Heart Failure: The ADMIRE-HFX Study. J Nucl Med. 2015;56:1011–1018. [PubMed] [Google Scholar]
182. Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI, Shimamoto K. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med. 2001;42:1757–1767. [PubMed] [Google Scholar]
183. Fallavollita JA, Heavey BM, Luisi AJ, Jr, Michalek SM, Baldwa S, Mashtare TL, Jr, Hutson AD, Dekemp RA, Haka MS, Sajjad M, Cimato TR, Curtis AB, Cain ME, Canty JM., Jr Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol. 2014;63:141–149. [PMC free article] [PubMed] [Google Scholar]
184. Fallavollita JA, Dare JD, Carter RL, Baldwa S, Canty JM., Jr Denervated Myocardium Is Preferentially Associated With Sudden Cardiac Arrest in Ischemic Cardiomyopathy: A Pilot Competing Risks Analysis of Cause-Specific Mortality. Circ Cardiovasc Imaging. 2017:10. [PMC free article] [PubMed] [Google Scholar]
185. Cain ME. Impact of denervated myocardium on improving risk stratification for sudden cardiac death. Trans Am Clin Climatol Assoc. 2014;125:141–53; discussion 153. [PMC free article] [PubMed] [Google Scholar]
186. Seo M, Yamada T, Tamaki S, Watanabe T, Morita T, Furukawa Y, Kawasaki M, Kikuchi A, Kawai T, Abe M, Nakamura J, Yamamoto K, Kayama K, Kawahira M, Tanabe K, Kimura T, Ueda K, Sakamoto D, Sakata Y, f*ckunami M. Prognostic significance of cardiac I-123-metaiodobenzylguanidine imaging in patients with reduced, mid-range, and preserved left ventricular ejection fraction admitted for acute decompensated heart failure: a prospective study in Osaka Prefectural Acute Heart Failure Registry (OPAR) Eur Heart J Cardiovasc Imaging. 2020 [PubMed] [Google Scholar]
187. Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, Manzano L, McMurray JJV, Ruschitzka F, van Veldhuisen DJ, von Lueder TG, Böhm M, Andersson B, Kjekshus J, Packer M, Rigby AS, Rosano G, Wedel H, Hjalmarson Å, Wikstrand J, Kotecha D. Beta-blockers in Heart Failure Collaborative Group. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39:26–35. [PMC free article] [PubMed] [Google Scholar]
188. Ernst G. Heart-Rate Variability-More than Heart Beats? Front Public Health. 2017;5:240. [PMC free article] [PubMed] [Google Scholar]
189. Shaffer F, McCraty R, Zerr CL. A healthy heart is not a metronome: an integrative review of the heart's anatomy and heart rate variability. Front Psychol. 2014;5:1040. [PMC free article] [PubMed] [Google Scholar]
190. Rajendra Acharya U, Paul Joseph K, Kannathal N, Lim CM, Suri JS. Heart rate variability: a review. Med Biol Eng Comput. 2006;44:1031–1051. [PubMed] [Google Scholar]
191. Shaffer F, Ginsberg JP. An Overview of Heart Rate Variability Metrics and Norms. Front Public Health. 2017;5:258. [PMC free article] [PubMed] [Google Scholar]
192. Stys A, Stys T. Current clinical applications of heart rate variability. Clin Cardiol. 1998;21:719–724. [PMC free article] [PubMed] [Google Scholar]
193. Tsuji H, Larson MG, Venditti FJ, Jr, Manders ES, Evans JC, Feldman CL, Levy D. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation. 1996;94:2850–2855. [PubMed] [Google Scholar]
194. Sessa F, Anna V, Messina G, Cibelli G, Monda V, Marsala G, Ruberto M, Biondi A, Cascio O, Bertozzi G, Pisanelli D, Maglietta F, Messina A, Mollica MP, Salerno M. Heart rate variability as predictive factor for sudden cardiac death. Aging (Albany NY) 2018;10:166–177. [PMC free article] [PubMed] [Google Scholar]
195. Hillebrand S, Gast KB, de Mutsert R, Swenne CA, Jukema JW, Middeldorp S, Rosendaal FR, Dekkers OM. Heart rate variability and first cardiovascular event in populations without known cardiovascular disease: meta-analysis and dose-response meta-regression. Europace. 2013;15:742–749. [PubMed] [Google Scholar]
196. Patel VN, Pierce BR, Bodapati RK, Brown DL, Ives DG, Stein PK. Association of Holter-Derived Heart Rate Variability Parameters With the Development of Congestive Heart Failure in the Cardiovascular Health Study. JACC Heart Fail. 2017;5:423–431. [PMC free article] [PubMed] [Google Scholar]
197. Nolan J, Batin PD, Andrews R, Lindsay SJ, Brooksby P, Mullen M, Baig W, Flapan AD, Cowley A, Prescott RJ, Neilson JM, Fox KA. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart) Circulation. 1998;98:1510–1516. [PubMed] [Google Scholar]
198. Palacios M, Friedrich H, Götze C, Vallverdú M, de Luna AB, Caminal P, Hoyer D. Changes of autonomic information flow due to idiopathic dilated cardiomyopathy. Physiol Meas. 2007;28:677–688. [PubMed] [Google Scholar]
199. La Rovere MT, Pinna GD, Maestri R, Mortara A, Capomolla S, Febo O, Ferrari R, Franchini M, Gnemmi M, Opasich C, Riccardi PG, Traversi E, Cobelli F. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation. 2003;107:565–570. [PubMed] [Google Scholar]
200. Ponikowski P, Anker SD, Chua TP, Szelemej R, Piepoli M, Adamopoulos S, Webb-Peploe K, Harrington D, Banasiak W, Wrabec K, Coats AJ. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1997;79:1645–1650. [PubMed] [Google Scholar]
201. Ponikowski P, Anker SD, Amadi A, Chua TP, Cerquetani E, Ondusova D, O'Sullivan C, Adamopoulos S, Piepoli M, Coats AJ. Heart rhythms, ventricular arrhythmias, and death in chronic heart failure. J Card Fail. 1996;2:177–183. [PubMed] [Google Scholar]
202. Aronson D, Mittleman MA, Burger AJ. Measures of heart period variability as predictors of mortality in hospitalized patients with decompensated congestive heart failure. Am J Cardiol. 2004;93:59–63. [PubMed] [Google Scholar]
203. Pousset F, Copie X, Lechat P, Jaillon P, Boissel JP, Hetzel M, Fillette F, Remme W, Guize L, Le Heuzey JY. Effects of bisoprolol on heart rate variability in heart failure. Am J Cardiol. 1996;77:612–617. [PubMed] [Google Scholar]
204. Aronson D, Burger AJ. Effect of beta-blockade on heart rate variability in decompensated heart failure. Int J Cardiol. 2001;79:31–39. [PubMed] [Google Scholar]
205. Hayano J, Yuda E. Pitfalls of assessment of autonomic function by heart rate variability. J Physiol Anthropol. 2019;38:3. [PMC free article] [PubMed] [Google Scholar]
206. Lombardi F, Mortara A. Heart rate variability and cardiac failure. Heart. 1998;80:213–214. [PMC free article] [PubMed] [Google Scholar]
207. Sarhene M, Wang Y, Wei J, Huang Y, Li M, Li L, Acheampong E, Zhengcan Z, Xiaoyan Q, Yunsheng X, Jingyuan M, Xiumei G, Guanwei F. Biomarkers in heart failure: the past, current and future. Heart Fail Rev. 2019;24:867–903. [PubMed] [Google Scholar]
208. Iqbal N, Wentworth B, Choudhary R, Landa Ade L, Kipper B, Fard A, Maisel AS. Cardiac biomarkers: new tools for heart failure management. Cardiovasc Diagn Ther. 2012;2:147–164. [PMC free article] [PubMed] [Google Scholar]
209. Matsush*ta M, Shirakabe A, Kobayashi N, Okazaki H, Shibata Y, Goda H, Shigihara S, Asano K, Tani K, Kiuchi K, Okajima F, Hata N, Asai K, Shimizu W. Mechanisms of Urgently Presenting Acute Heart Failure. Int Heart J. 2020;61:316–324. [PubMed] [Google Scholar]
210. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:VI40–VI48. [PubMed] [Google Scholar]
211. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT) Circulation. 2003;107:1278–1283. [PubMed] [Google Scholar]
212. Givertz MM, Braunwald E. Neurohormones in heart failure: predicting outcomes, optimizing care. Eur Heart J. 2004;25:281–282. [PubMed] [Google Scholar]
213. Hjemdahl P. Plasma catecholamines--analytical challenges and physiological limitations. Baillieres Clin Endocrinol Metab. 1993;7:307–353. [PubMed] [Google Scholar]
214. Habecker BA, Anderson ME, Birren SJ, f*ckuda K, Herring N, Hoover DB, Kanazawa H, Paterson DJ, Ripplinger CM. Molecular and cellular neurocardiology: development, and cellular and molecular adaptations to heart disease. J Physiol. 2016;594:3853–3875. [PMC free article] [PubMed] [Google Scholar]
215. Tan CMJ, Green P, Tapoulal N, Lewandowski AJ, Leeson P, Herring N. The Role of Neuropeptide Y in Cardiovascular Health and Disease. Front Physiol. 2018;9:1281. [PMC free article] [PubMed] [Google Scholar]
216. Herring N, Lokale MN, Danson EJ, Heaton DA, Paterson DJ. Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway. J Mol Cell Cardiol. 2008;44:477–485. [PubMed] [Google Scholar]
217. Heredia Mdel P, Delgado C, Pereira L, Perrier R, Richard S, Vassort G, Bénitah JP, Gómez AM. Neuropeptide Y rapidly enhances [Ca2+]i transients and Ca2+ sparks in adult rat ventricular myocytes through Y1 receptor and PLC activation. J Mol Cell Cardiol. 2005;38:205–212. [PubMed] [Google Scholar]
218. Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc Natl Acad Sci USA. 1982;79:5485–5489. [PMC free article] [PubMed] [Google Scholar]
219. Alasvand M, Javanmard SH, Rashidi B, Khazaei M. Myocardial capillary density after neuropeptide Y antagonist administration in normal and high-fat diet C57BL6 mice. Adv Biomed Res. 2016;5:165. [PMC free article] [PubMed] [Google Scholar]
220. Saraf R, Mahmood F, Amir R, Matyal R. Neuropeptide Y is an angiogenic factor in cardiovascular regeneration. Eur J Pharmacol. 2016;776:64–70. [PubMed] [Google Scholar]
221. Jacques D, D'Orléans-Juste P, Magder S, Bkaily G. Neuropeptide Y and its receptors in ventricular endocardial endothelial cells. Can J Physiol Pharmacol. 2017;95:1224–1229. [PubMed] [Google Scholar]
222. Feng Q, Lambert ML, Callow ID, Arnold JM. Venous neuropeptide Y receptor responsiveness in patients with chronic heart failure. Clin Pharmacol Ther. 2000;67:292–298. [PubMed] [Google Scholar]
223. Feng QP, Sun XY, Hedner T. Cardiovascular responses and interactions by neuropeptide Y in rats with congestive heart failure. Blood Press. 1996;5:312–318. [PubMed] [Google Scholar]
224. Shanks J, Herring N. Peripheral cardiac sympathetic hyperactivity in cardiovascular disease: role of neuropeptides. Am J Physiol Regul Integr Comp Physiol. 2013;305:R1411–R1420. [PMC free article] [PubMed] [Google Scholar]
225. Feng QP, Hedner T, Andersson B, Lundberg JM, Waagstein F. Cardiac neuropeptide Y and noradrenaline balance in patients with congestive heart failure. Br Heart J. 1994;71:261–267. [PMC free article] [PubMed] [Google Scholar]
226. Ullman B, Lindvall K, Lundberg JM, Sigurdsson A, Swedberg K. Response of plasma neuropeptide Y and noradrenaline to dynamic exercise and ramipril treatment in patients with congestive heart failure. Clin Physiol. 1994;14:123–134. [PubMed] [Google Scholar]
227. Maisel AS, Scott NA, Motulsky HJ, Michel MC, Boublik JH, Rivier JE, Ziegler M, Allen RS, Brown MR. Elevation of plasma neuropeptide Y levels in congestive heart failure. Am J Med. 1989;86:43–48. [PubMed] [Google Scholar]
228. Ajijola OA, Chatterjee NA, Gonzales MJ, Gornbein J, Liu K, Li D, Paterson DJ, Shivkumar K, Singh JP, Herring N. Coronary Sinus Neuropeptide Y Levels and Adverse Outcomes in Patients With Stable Chronic Heart Failure. JAMA Cardiol. 2019 [PMC free article] [PubMed] [Google Scholar]
229. Morton GJ, Schwartz MW. The NPY/AgRP neuron and energy homeostasis. Int J Obes Relat Metab Disord. 2001;25 Suppl 5:S56–S62. [PubMed] [Google Scholar]
230. Morris MJ, Cox HS, Lambert GW, Kaye DM, Jennings GL, Meredith IT, Esler MD. Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans. Hypertension. 1997;29:137–143. [PubMed] [Google Scholar]
231. Dubois-Randé JL, Comoy E, Merlet P, Benvenuti C, Carville C, Hittinger L, Macquin-Mavier I, Bohuon C, Castaigne A. Relationship among neuropeptide Y, catecholamines and haemodynamics in congestive heart failure. Eur Heart J. 1992;13:1233–1238. [PubMed] [Google Scholar]
232. Medzikovic L, van Roomen C, Baartscheer A, van Loenen PB, de Vos J, Bakker ENTP, Koenis DS, Damanafshan A, Creemers EE, Arkenbout EK, de Vries CJM, de Waard V. Nur77 protects against adverse cardiac remodelling by limiting neuropeptide Y signalling in the sympathoadrenal-cardiac axis. Cardiovasc Res. 2018;114:1617–1628. [PubMed] [Google Scholar]
233. Smith-White MA, Iismaa TP, Potter EK. Galanin and neuropeptide Y reduce cholinergic transmission in the heart of the anaesthetised mouse. Br J Pharmacol. 2003;140:170–178. [PMC free article] [PubMed] [Google Scholar]
234. Herring N, Cranley J, Lokale MN, Li D, Shanks J, Alston EN, Girard BM, Carter E, Parsons RL, Habecker BA, Paterson DJ. The cardiac sympathetic co-transmitter galanin reduces acetylcholine release and vagal bradycardia: implications for neural control of cardiac excitability. J Mol Cell Cardiol. 2012;52:667–676. [PMC free article] [PubMed] [Google Scholar]
235. Díaz-Cabiale Z, Parrado C, Narváez M, Millón C, Puigcerver A, f*cke K, Narváez JA. Neurochemical modulation of central cardiovascular control: the integrative role of galanin. Exp Suppl. 2010;102:113–131. [PubMed] [Google Scholar]
236. Özkaramanlı Gür D, Sağbaş M, Akyüz A, Güzel S, Alpsoy Ş, Güler N. Role of sympathetic cotransmitter galanin on autonomic balance in heart failure: an active player or a bystander? Anatol J Cardiol. 2017;18:281–288. [PMC free article] [PubMed] [Google Scholar]
237. Chan NY, Robador PA, Levi R. Natriuretic peptide-induced catecholamine release from cardiac sympathetic neurons: inhibition by histamine H3 and H4 receptor activation. J Pharmacol Exp Ther. 2012;343:568–577. [PMC free article] [PubMed] [Google Scholar]
238. Tyrrell C, Toyooka A, Khan F, Thornburg KL, Mudd JO, Hasan W. The neuropeptide galanin promotes an anti-thrombotic phenotype on endocardial endothelial cells from heart failure patients. Auton Neurosci. 2017;206:35–42. [PubMed] [Google Scholar]
239. Chen A, Li M, Song L, Zhang Y, Luo Z, Zhang W, Chen Y, He B. Effects of the Galanin Receptor Antagonist M40 on Cardiac Function and Remodeling in Rats with Heart Failure. Cardiovasc Ther. 2015;33:288–293. [PubMed] [Google Scholar]
240. Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ. Endothelin. Pharmacol Rev. 2016;68:357–418. [PMC free article] [PubMed] [Google Scholar]
241. Agapitov AV, Haynes WG. Role of endothelin in cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2002;3:1–15. [PubMed] [Google Scholar]
242. Dhaun N, Webb DJ. Endothelins in cardiovascular biology and therapeutics. Nat Rev Cardiol. 2019;16:491–502. [PubMed] [Google Scholar]
243. Koseki C, Imai M, Hirata Y, Yanagisawa M, Masaki T. Autoradiographic distribution in rat tissues of binding sites for endothelin: a neuropeptide? Am J Physiol. 1989;256:R858–R866. [PubMed] [Google Scholar]
244. Lehmann LH, Stanmore DA, Backs J. The role of endothelin-1 in the sympathetic nervous system in the heart. Life Sci. 2014;118:165–172. [PubMed] [Google Scholar]
245. Lepailleur-Enouf D, Egidy G, Philippe M, Louedec L, Henry J, Mulder P, Michel J. Pulmonary endothelinergic system in experimental congestive heart failure. Cardiovasc Res. 2001;49:330–339. [PubMed] [Google Scholar]
246. Stangl K, Dschietzig T, Richter C, Laule M, Stangl V, Tanis E, Baumann G, Felix SB. Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure: acute effects of vasodilator therapy. Circulation. 2000;102:1132–1138. [PubMed] [Google Scholar]
247. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732–1739. [PubMed] [Google Scholar]
248. Lim K, van den Buuse M, Head GA. Effect of Endothelin-1 on Baroreflexes and the Cardiovascular Action of Clonidine in Conscious Rabbits. Front Physiol. 2016;7:321. [PMC free article] [PubMed] [Google Scholar]
249. Mosqueda-Garcia R, Inagami T, Appalsamy M, Sugiura M, Robertson RM. Endothelin as a neuropeptide. Cardiovascular effects in the brainstem of normotensive rats. Circ Res. 1993;72:20–35. [PubMed] [Google Scholar]
250. Friedrich EB, Muders F, Luchner A, Dietl O, Riegger GA, Elsner D. Contribution of the endothelin system to the renal hypoperfusion associated with experimental congestive heart failure. J Cardiovasc Pharmacol. 1999;34:612–617. [PubMed] [Google Scholar]
251. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugish*ta Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 1996;384:353–355. [PubMed] [Google Scholar]
252. Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Macé B, Comoy E, Letac B, Thuillez C. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 1997;96:1976–1982. [PubMed] [Google Scholar]
253. Yamauchi-Kohno R, Miyauchi T, Hoshino T, Kobayashi T, Aihara H, Sakai S, Yabana H, Goto K, Sugish*ta Y, Murata S. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function. Circulation. 1999;99:2171–2176. [PubMed] [Google Scholar]
254. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504–509. [PubMed] [Google Scholar]
255. Abukar Y, May CN, Ramchandra R. Role of endothelin-1 in mediating changes in cardiac sympathetic nerve activity in heart failure. Am J Physiol Regul Integr Comp Physiol. 2016;310:R94–R99. [PubMed] [Google Scholar]
256. Tsuchiyama Y, Kasamatsu K, Hano T, Nishio I. Acute effect of endothelin AB antagonist on sympathetic outflow in conscious rats with heart failure. Circ J. 2002;66:841–845. [PubMed] [Google Scholar]
257. Fraccarollo D, Bauersachs J, Kellner M, Galuppo P, Ertl G. Cardioprotection by long-term ET(A) receptor blockade and ACE inhibition in rats with congestive heart failure: mono- versus combination therapy. Cardiovasc Res. 2002;54:85–94. [PubMed] [Google Scholar]
258. Lehmann LH, Rostosky JS, Buss SJ, Kreusser MM, Krebs J, Mier W, Enseleit F, Spiger K, Hardt SE, Wieland T, Haass M, Lüscher TF, Schneider MD, Parlato R, Gröne HJ, Haberkorn U, Yanagisawa M, Katus HA, Backs J. Essential role of sympathetic endothelin A receptors for adverse cardiac remodeling. Proc Natl Acad Sci USA. 2014;111:13499–13504. [PMC free article] [PubMed] [Google Scholar]
259. Kopp UC, Cicha MZ, Jones SY. Activation of endothelin A receptors contributes to impaired responsiveness of renal mechanosensory nerves in congestive heart failure. Can J Physiol Pharmacol. 2010;88:622–629. [PMC free article] [PubMed] [Google Scholar]
260. Backs J, Bresch E, Lutz M, Kristen AV, Haass M. Endothelin-1 inhibits the neuronal norepinephrine transporter in hearts of male rats. Cardiovasc Res. 2005;67:283–290. [PubMed] [Google Scholar]
261. Khalil RA. Modulators of the vascular endothelin receptor in blood pressure regulation and hypertension. Curr Mol Pharmacol. 2011;4:176–186. [PMC free article] [PubMed] [Google Scholar]
262. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I VERITAS Investigators. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA. 2007;298:2009–2019. [PubMed] [Google Scholar]
263. O'Connor CM, Gattis WA, Adams KF, Jr, Hasselblad V, Chandler B, Frey A, Kobrin I, Rainisio M, Shah MR, Teerlink J, Gheorghiade M Randomized Intravenous TeZosentan Study-4 Investigators. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4) J Am Coll Cardiol. 2003;41:1452–1457. [PubMed] [Google Scholar]
264. Perez AL, Grodin JL, Wu Y, Hernandez AF, Butler J, Metra M, Felker GM, Voors AA, McMurray JJ, Armstrong PW, Starling RC, O'Connor CM, Tang WH. Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. Eur J Heart Fail. 2016;18:290–297. [PubMed] [Google Scholar]
265. Olivier A, Girerd N, Michel JB, Ketelslegers JM, Fay R, Vincent J, Bramlage P, Pitt B, Zannad F, Rossignol P EPHESUS Investigators. Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Int J Cardiol. 2017;241:344–350. [PubMed] [Google Scholar]
266. Plumpton C, Haynes WG, Webb DJ, Davenport AP. Measurement of C-terminal fragment of big endothelin-1: a novel method for assessing the generation of endothelin-1 in humans. J Cardiovasc Pharmacol. 1995;26 Suppl 3:S34–S36. [PubMed] [Google Scholar]
267. Wei CM, Lerman A, Rodeheffer RJ, McGregor CG, Brandt RR, Wright S, Heublein DM, Kao PC, Edwards WD, Burnett JC., Jr Endothelin in human congestive heart failure. Circulation. 1994;89:1580–1586. [PubMed] [Google Scholar]
268. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure. Circulation. 1992;85:1374–1379. [PubMed] [Google Scholar]
269. Jankowska EA, Filippatos GS, von Haehling S, Papassotiriou J, Morgenthaler NG, Cicoira M, Schefold JC, Rozentryt P, Ponikowska B, Doehner W, Banasiak W, Hartmann O, Struck J, Bergmann A, Anker SD, Ponikowski P. Identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1. PLoS One. 2011;6:e14506. [PMC free article] [PubMed] [Google Scholar]
270. Masson S, Latini R, Anand IS, Barlera S, Judd D, Salio M, Perticone F, Perini G, Tognoni G, Cohn JN Val-HeFT investigators. The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT) J Card Fail. 2006;12:375–380. [PubMed] [Google Scholar]
271. Van Beneden R, Gurné O, Selvais PL, Ahn SA, Robert AR, Ketelslegers JM, Pouleur HG, Rousseau MF. Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. J Card Fail. 2004;10:490–495. [PubMed] [Google Scholar]
272. Zhang CL, Xie S, Qiao X, An YM, Zhang Y, Li L, Guo XB, Zhang FC, Wu LL. Plasma endothelin-1-related peptides as the prognostic biomarkers for heart failure: A PRISMA-compliant meta-analysis. Medicine (Baltimore) 2017;96:e9342. [PMC free article] [PubMed] [Google Scholar]
273. Xiong B, Nie D, Cao Y, Zou Y, Yao Y, Tan J, Qian J, Rong S, Wang C, Huang J. Clinical and Hemodynamic Effects of Endothelin Receptor Antagonists in Patients With Heart Failure. Int Heart J. 2017;58:400–408. [PubMed] [Google Scholar]
274. Chowdhury MA, Moukarbel GV, Gupta R, Frank SM, Anderson AM, Liu LC, Khouri SJ. Endothelin 1 Is Associated with Heart Failure Hospitalization and Long-Term Mortality in Patients with Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension. Cardiology. 2019;143:124–133. [PubMed] [Google Scholar]
275. Obokata M, Kane GC, Reddy YNV, Melenovsky V, Olson TP, Jarolim P, Borlaug BA. The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction. Eur Heart J. 2019;40:3707–3717. [PMC free article] [PubMed] [Google Scholar]
276. Jankowich MD, Wu WC, Choudhary G. Association of Elevated Plasma Endothelin-1 Levels With Pulmonary Hypertension, Mortality, and Heart Failure in African American Individuals: The Jackson Heart Study. JAMA Cardiol. 2016;1:461–469. [PubMed] [Google Scholar]
277. Omland T. Targeting the endothelin system: a step towards a precision medicine approach in heart failure with preserved ejection fraction? Eur Heart J. 2019;40:3718–3720. [PubMed] [Google Scholar]
278. Valero-Munoz M, Li S, Wilson RM, Boldbaatar B, Iglarz M, Sam F. Dual Endothelin-A/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2016:9. [PMC free article] [PubMed] [Google Scholar]
279. Zile MR, Bourge RC, Redfield MM, Zhou D, Baicu CF, Little WC. Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction. JACC Heart Fail. 2014;2:123–130. [PubMed] [Google Scholar]
280. Koller B, Steringer-Mascherbauer R, Ebner CH, Weber T, Ammer M, Eichinger J, Pretsch I, Herold M, Schwaiger J, Ulmer H, Grander W. Pilot Study of Endothelin Receptor Blockade in Heart Failure with Diastolic Dysfunction and Pulmonary Hypertension (BADDHY-Trial) Heart Lung Circ. 2017;26:433–441. [PubMed] [Google Scholar]
281. Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Parmer RJ. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest. 1997;100:1623–1633. [PMC free article] [PubMed] [Google Scholar]
282. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348:1134–1149. [PubMed] [Google Scholar]
283. Mahata SK, Corti A. Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation. Ann N Y Acad Sci. 2019;1455:34–58. [PMC free article] [PubMed] [Google Scholar]
284. Takiyyuddin MA, Brown MR, Dinh TQ, Cervenka JH, Braun SD, Parmer RJ, Kennedy B, O'Connor DT. Sympatho-adrenal secretion in humans: factors governing catecholamine and storage vesicle peptide co-release. J Auton Pharmacol. 1994;14:187–200. [PubMed] [Google Scholar]
285. Ceconi C, Ferrari R, Bachetti T, Opasich C, Volterrani M, Colombo B, Parrinello G, Corti A. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J. 2002;23:967–974. [PubMed] [Google Scholar]
286. Omland T, Dickstein K, Syversen U. Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. Am J Med. 2003;114:25–30. [PubMed] [Google Scholar]
287. Estensen ME, Hognestad A, Syversen U, Squire I, Ng L, Kjekshus J, Dickstein K, Omland T. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am Heart J. 2006;152:927.e1–927.e6. [PubMed] [Google Scholar]
288. Pieroni M, Corti A, Tota B, Curnis F, Angelone T, Colombo B, Cerra MC, Bellocci F, Crea F, Maseri A. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J. 2007;28:1117–1127. [PubMed] [Google Scholar]
289. Mahata SK, Mahata M, Fung MM, O'Connor DT. Catestatin: a multifunctional peptide from chromogranin A. Regul Pept. 2010;162:33–43. [PMC free article] [PubMed] [Google Scholar]
290. Mahata SK, Kiranmayi M, Mahapatra NR. Catestatin: A Master Regulator of Cardiovascular Functions. Curr Med Chem. 2018;25:1352–1374. [PubMed] [Google Scholar]
291. Fung MM, Salem RM, Mehtani P, Thomas B, Lu CF, Perez B, Rao F, Stridsberg M, Ziegler MG, Mahata SK, O'Connor DT. Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin Exp Hypertens. 2010;32:278–287. [PMC free article] [PubMed] [Google Scholar]
292. Krüger PG, Mahata SK, Helle KB. Catestatin (CgA344-364) stimulates rat mast cell release of histamine in a manner comparable to mastoparan and other cationic charged neuropeptides. Regul Pept. 2003;114:29–35. [PubMed] [Google Scholar]
293. Kiranmayi M, Chirasani VR, Allu PK, Subramanian L, Martelli EE, Sahu BS, Vishnuprabu D, Kumaragurubaran R, Sharma S, Bodhini D, Dixit M, Munirajan AK, Khullar M, Radha V, Mohan V, Mullasari AS, Naga Prasad SV, Senapati S, Mahapatra NR. Catestatin Gly364Ser Variant Alters Systemic Blood Pressure and the Risk for Hypertension in Human Populations via Endothelial Nitric Oxide Pathway. Hypertension. 2016;68:334–347. [PMC free article] [PubMed] [Google Scholar]
294. Kennedy BP, Mahata SK, O'Connor DT, Ziegler MG. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides. 1998;19:1241–1248. [PubMed] [Google Scholar]
295. Troger J, Theurl M, Kirchmair R, Pasqua T, Tota B, Angelone T, Cerra MC, Nowosielski Y, Mätzler R, Troger J, Gayen JR, Trudeau V, Corti A, Helle KB. Granin-derived peptides. Prog Neurobiol. 2017;154:37–61. [PubMed] [Google Scholar]
296. Mahapatra NR, Mahata M, Mahata SK, O'Connor DT. The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters. J Hypertens. 2006;24:895–904. [PubMed] [Google Scholar]
297. Gaede AH, Pilowsky PM. Catestatin in rat RVLM is sympathoexcitatory, increases barosensitivity, and attenuates chemosensitivity and the somatosympathetic reflex. Am J Physiol Regul Integr Comp Physiol. 2010;299:R1538–R1545. [PubMed] [Google Scholar]
298. Gaede AH, Pilowsky PM. Catestatin, a chromogranin A-derived peptide, is sympathoinhibitory and attenuates sympathetic barosensitivity and the chemoreflex in rat CVLM. Am J Physiol Regul Integr Comp Physiol. 2012;302:R365–R372. [PubMed] [Google Scholar]
299. Bassino E, Fornero S, Gallo MP, Ramella R, Mahata SK, Tota B, Levi R, Alloatti G. A novel catestatin-induced antiadrenergic mechanism triggered by the endothelial PI3K-eNOS pathway in the myocardium. Cardiovasc Res. 2011;91:617–624. [PMC free article] [PubMed] [Google Scholar]
300. Imbrogno S, Garofalo F, Cerra MC, Mahata SK, Tota B. The catecholamine release-inhibitory peptide catestatin (chromogranin A344-363) modulates myocardial function in fish. J Exp Biol. 2010;213:3636–3643. [PubMed] [Google Scholar]
301. Bassino E, Fornero S, Gallo MP, Gallina C, Femminò S, Levi R, Tota B, Alloatti G. Catestatin exerts direct protective effects on rat cardiomyocytes undergoing ischemia/reperfusion by stimulating PI3K-Akt-GSK3β pathway and preserving mitochondrial membrane potential. PLoS One. 2015;10:e0119790. [PMC free article] [PubMed] [Google Scholar]
302. Theurl M, Schgoer W, Albrecht K, Jeschke J, Egger M, Beer AG, Vasiljevic D, Rong S, Wolf AM, Bahlmann FH, Patsch JR, Wolf D, Schratzberger P, Mahata SK, Kirchmair R. The neuropeptide catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor-dependent mechanism. Circ Res. 2010;107:1326–1335. [PMC free article] [PubMed] [Google Scholar]
303. Guo X, Zhou C, Sun N. The neuropeptide catestatin promotes vascular smooth muscle cell proliferation through the Ca2+-calcineurin-NFAT signaling pathway. Biochem Biophys Res Commun. 2011;407:807–812. [PubMed] [Google Scholar]
304. Chen H, Liu D, Ge L, Wang T, Ma Z, Han Y, Duan Y, Xu X, Liu W, Yuan J, Liu J, Li R, Du R. Catestatin prevents endothelial inflammation and promotes thrombus resolution in acute pulmonary embolism in mice. Biosci Rep. 2019:39. [PMC free article] [PubMed] [Google Scholar]
305. Chen Y, Wang X, Yang C, Su X, Yang W, Dai Y, Han H, Jiang J, Lu L, Wang H, Chen Q, Jin W. Decreased circulating catestatin levels are associated with coronary artery disease: The emerging anti-inflammatory role. Atherosclerosis. 2019;281:78–88. [PubMed] [Google Scholar]
306. Chu SY, Peng F, Wang J, Liu L, Meng L, Zhao J, Han XN, Ding WH. Catestatin in defense of oxidative-stress-induced apoptosis: A novel mechanism by activating the beta2 adrenergic receptor and PKB/Akt pathway in ischemic-reperfused myocardium. Peptides. 2020;123:170200. [PubMed] [Google Scholar]
307. Alam MJ, Gupta R, Mahapatra NR, Goswami SK. Catestatin reverses the hypertrophic effects of norepinephrine in H9c2 cardiac myoblasts by modulating the adrenergic signaling. Mol Cell Biochem. 2020;464:205–219. [PubMed] [Google Scholar]
308. Angelone T, Quintieri AM, Pasqua T, Gentile S, Tota B, Mahata SK, Cerra MC. Phosphodiesterase type-2 and NO-dependent S-nitrosylation mediate the cardioinhibition of the antihypertensive catestatin. Am J Physiol Heart Circ Physiol. 2012;302:H431–H442. [PubMed] [Google Scholar]
309. Wang D, Liu T, Shi S, Li R, Shan Y, Huang Y, Hu D, Huang C. Chronic Administration of Catestatin Improves Autonomic Function and Exerts Cardioprotective Effects in Myocardial Infarction Rats. J Cardiovasc Pharmacol Ther. 2016;21:526–535. [PubMed] [Google Scholar]
310. Dev NB, Mir SA, Gayen JR, Siddiqui JA, Mustapic M, Vaingankar SM. Cardiac electrical activity in a genomically "humanized" chromogranin a monogenic mouse model with hyperadrenergic hypertension. J Cardiovasc Transl Res. 2014;7:483–493. [PMC free article] [PubMed] [Google Scholar]
311. Pei Z, Ma D, Ji L, Zhang J, Su J, Xue W, Chen X, Wang W. Usefulness of catestatin to predict malignant arrhythmia in patients with acute myocardial infarction. Peptides. 2014;55:131–135. [PubMed] [Google Scholar]
312. Zhu D, Wang F, Yu H, Mi L, Gao W. Catestatin is useful in detecting patients with stage B heart failure. Biomarkers. 2011;16:691–697. [PubMed] [Google Scholar]
313. Liu L, Ding W, Li R, Ye X, Zhao J, Jiang J, Meng L, Wang J, Chu S, Han X, Peng F. Plasma levels and diagnostic value of catestatin in patients with heart failure. Peptides. 2013;46:20–25. [PubMed] [Google Scholar]
314. Borovac JA, Glavas D, Susilovic Grabovac Z, Supe Domic D, D'Amario D, Bozic J. Catestatin in Acutely Decompensated Heart Failure Patients: Insights from the CATSTAT-HF Study. J Clin Med. 2019:8. [PMC free article] [PubMed] [Google Scholar]
315. Meng L, Ye XJ, Ding WH, Yang Y, Di BB, Liu L, Huo Y. Plasma catecholamine release-inhibitory peptide catestatin in patients with essential hypertension. J Cardiovasc Med (Hagerstown) 2011;12:643–647. [PubMed] [Google Scholar]
316. Peng F, Chu S, Ding W, Liu L, Zhao J, Cui X, Li R, Wang J. The predictive value of plasma catestatin for all-cause and cardiac deaths in chronic heart failure patients. Peptides. 2016;86:112–117. [PubMed] [Google Scholar]
